Novo Nordisk

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy, and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 45,000 people in 80 countries and markets its products in around 170 countries.

Sustainability at Novo Nordisk

Novo Nordisk is committed to driving change to defeat diabetes and other serious chronic diseases. The company integrates sustainability into its business strategy and operations. Novo Nordisk has been recognized for its efforts in sustainability and has received several accolades, including being listed on the Dow Jones Sustainability Indices (DJSI) for several years.

• Novo Nordisk aims to have zero environmental impact by 2030.
• The company has set ambitious targets to reduce its carbon footprint and is working towards using 100% renewable power at all production sites.
• Novo Nordisk publishes an annual ESG report detailing its environmental, social, and governance performance.
• The company is a signatory to the UN Global Compact and adheres to its principles on human rights, labor, environment, and anti-corruption.

For more detailed information on Novo Nordisk's sustainability initiatives, please refer to their latest ESG report available on their official website.